+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroesophageal Reflux Disease Therapeutics Market by Treatment Type, Distribution Channel, Route of Administration, Dosage Form, Patient End User - Global Forecast to 2030- Product Image
Gastroesophageal Reflux Disease Therapeutics Market by Treatment Type, Distribution Channel, Route of Administration, Dosage Form, Patient End User - Global Forecast to 2030- Product Image
Sale

Gastroesophageal Reflux Disease Therapeutics Market by Treatment Type, Distribution Channel, Route of Administration, Dosage Form, Patient End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5454843
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Gastroesophageal Reflux Disease (GERD) therapeutics market is in a phase of ongoing transformation, marked by innovation in treatment modalities, digital health integration, and changing global supply chain strategies. Senior decision-makers in pharmaceuticals, healthcare, and investment sectors must closely track these trends to position themselves for growth and resilience within this evolving landscape.

Market Snapshot: Gastroesophageal Reflux Disease Therapeutics Market Size and Growth

The GERD therapeutics market progressed from USD 6.14 billion in 2024 to USD 6.45 billion in 2025. It is forecasted to expand further at a CAGR of 5.03% and reach USD 8.24 billion by 2030. Market growth is fueled by expanded formularies, advanced drug delivery systems, and increased deployment of digital health tools, strengthening the sector’s global presence and competitive outlook.

Scope & Segmentation

This comprehensive report covers every major aspect influencing the GERD therapeutics market. The following segments and categories form the backbone of competitive analysis and opportunity mapping:

  • Treatment Types: Antacids, H2 Receptor Antagonists (Branded, Generic), Prokinetics, Proton Pump Inhibitors (Branded, Generic)
  • Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • Route of Administration: Intravenous, Oral
  • Dosage Forms: Capsule, Liquid, Suspension, Tablet
  • Patient End Users: Home Care Settings, Hospitals, Specialty Clinics
  • Regional Markets: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Industry Players: AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Johnson & Johnson Services Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Merck Sharp & Dohme Corp., Novartis AG, Teva Pharmaceutical Industries Ltd.

Key Takeaways: Strategic Insights for Decision-Makers

  • The therapeutic landscape is diversifying rapidly, with next-generation treatment options extending beyond traditional symptom relief and focusing on molecular-level pathophysiology.
  • Digital health platforms and remote monitoring are redefining patient management, supporting adherence, and enabling evidence-driven decision-making for healthcare providers and payers.
  • Emergence of branded and generic alternatives within both H2 receptor antagonists and proton pump inhibitors is intensifying competition and introducing new pricing and market entry dynamics.
  • Collaborative R&D, co-development partnerships, and licensing agreements are mitigating operational risks for emerging biotech firms and accelerating commercialization pathways.
  • Distribution is shifting with the notable growth of online and direct-to-consumer models, while hospital pharmacies remain indispensable for acute and critical-care management.
  • Increasing geographic variation in regulatory and reimbursement environments is compelling firms to tailor market entry and commercialization strategies across key global regions.

Tariff Impact

New US tariffs on pharmaceutical inputs and finished products introduced in 2025 have led to an uptick in production costs, especially affecting proton pump inhibitors and innovative molecular entities. In response, companies are reengineering supply chains, exploring alternative sourcing, and, in some cases, moving manufacturing operations to mitigate tariff impacts. This shift is prompting long-term supplier agreements, increased domestic production investments, and renewed efforts towards supplier diversification, underscoring the importance of agile operating models.

Methodology & Data Sources

This report employs a robust methodology, integrating primary research from stakeholder interviews—including gastroenterologists, payers, and supply chain leaders—with secondary analysis from peer-reviewed journals, clinical trial data, regulatory disclosures, and proprietary industry databases. All findings have been triangulated for accuracy and consistency.

Why This Report Matters

  • Delivers actionable intelligence tailored for executives seeking a comprehensive understanding of global GERD therapeutics sector trends, opportunities, and threats.
  • Supports informed investment planning and strategic decision-making with granular insights on market forces, product innovation, commercialization pathways, and regional variations.
  • Enables organizations to benchmark competitive advantages, anticipate payer expectations, and align product pipelines with evolving patient and healthcare system demands.

Conclusion

The GERD therapeutics market is experiencing fundamental change, driven by scientific advancement and dynamic regulatory, economic, and competitive forces. Senior leaders are best positioned by embracing adaptive strategies and leveraging robust insights found in this report.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Antacids
8.3. H2 Receptor Antagonists
8.3.1. Branded
8.3.2. Generic
8.4. Prokinetics
8.5. Proton Pump Inhibitors
8.5.1. Branded
8.5.2. Generic
9. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Gastroesophageal Reflux Disease Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Liquid
11.4. Suspension
11.5. Tablet
12. Gastroesophageal Reflux Disease Therapeutics Market, by Patient End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Gastroesophageal Reflux Disease Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Johnson & Johnson Services, Inc.
16.3.4. Pfizer Inc.
16.3.5. Sanofi S.A.
16.3.6. GlaxoSmithKline plc
16.3.7. Bayer AG
16.3.8. Merck Sharp & Dohme Corp.
16.3.9. Novartis AG
16.3.10. Teva Pharmaceutical Industries Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 51. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 55. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 56. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 62. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 92. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 98. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 99. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 101. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 113. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 115. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 119. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 120. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 122. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 148. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 150. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 154. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 162. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 164. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 168. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 169. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 190. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 197. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 199. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 203. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 211. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 217. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 218. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 220. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 224. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 240. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 242. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 247. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 249. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 254. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA GASTROESOPHAGEAL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gastroesophageal Reflux Disease Therapeutics market report include:
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Bayer AG
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.24 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report - Product Image

Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Market Report 2025 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 132 Pages
  • Global
From
Gastroesophageal Reflux Disease (GERD) Market Report 2025 - Product Image

Gastroesophageal Reflux Disease (GERD) Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Gastroesophageal Reflux Disease Drug Market

Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the esophagus and stomach. GERD is a common disorder, and is often treated with medications that reduce the amount of acid produced in the stomach. These medications are part of the Gastrointestinal Drugs market. Gastrointestinal Drugs are used to treat a variety of digestive disorders, including GERD. These drugs can be divided into two categories: antacids and proton pump inhibitors (PPIs). Antacids are used to neutralize stomach acid, while PPIs are used to reduce the amount of acid produced in the stomach. Both types of drugs are available in both prescription and over-the-counter forms. The Gastroesophageal Reflux Disease Drug market is a subset of the Gastrointestinal Drugs market. This market includes both prescription and over-the-counter medications used to treat GERD. Some of the major companies in this market include AstraZeneca, GlaxoSmithKline, Pfizer, Merck, and Takeda. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.